Molecular Characterization of Advanced Stage Melanoma by Blood Sampling

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02862743

Acronym

MELCIRC

Enrollment

Registered

2016-08-11

Start date

2016-01-14

Completion date

2019-12-31

Last updated

2026-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Melanoma

Brief summary

Analysis of somatic mutations in tumors is currently indicated for daily practice in all metastatic melanoma. Actually, this research is limited to the mutation of three biomarkers validated by the l'Institut National du CAncer (INCA): BRAF, NRAS and CKIT. Moreover, in some cases it requires invasive biopsies. In this context, molecular characterization of a tumor material flowing (circulating tumor DNA and / or circulating tumor cells) could afford to benefit patients in the best conditions of current targeted therapies and future.

Detailed description

The main objective of this study will be to define the diagnostic sensitivity of a panel of biomarker on the circulating tumor DNA from peripheral blood. The secondary objectives of this study will be: * Study the concordance between mutations in circulating tumor DNA and mutations in tumor tissue - Study the associations between mutational profiles and clinical and histological features of melanoma. * Study the prognostic impact on survival of the identified genetic profile from the circulating tumor DNA

Interventions

OTHERpatients with metastatic melanoma

Blood sample to realize molecular characterization of melanoma

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patient with melanoma confirmed histologically * patient with metastatic melanoma (stage III unresectable or stage IV) * patient consenting to participate to the study * patient enrolled in the national healthcare insurance program * patient older than 18 years

Exclusion criteria

\- Metastatic tumor whose origin is doubtful (uncertain melanoma)

Design outcomes

Primary

Measure	Time frame	Description
Diagnostic sensitivity of a panel of biomarker on the circulating tumor DNA from peripheral blood	Day 0	Number of patients for which a circulating tumor DNA is detected (positivity of at least one marker of the panel)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026